KR102298473B1 - 제어 방출 제약 투여 형태 - Google Patents

제어 방출 제약 투여 형태 Download PDF

Info

Publication number
KR102298473B1
KR102298473B1 KR1020157028585A KR20157028585A KR102298473B1 KR 102298473 B1 KR102298473 B1 KR 102298473B1 KR 1020157028585 A KR1020157028585 A KR 1020157028585A KR 20157028585 A KR20157028585 A KR 20157028585A KR 102298473 B1 KR102298473 B1 KR 102298473B1
Authority
KR
South Korea
Prior art keywords
doxycycline
dosage form
weight
controlled release
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157028585A
Other languages
English (en)
Korean (ko)
Other versions
KR20160021074A (ko
Inventor
사지브 칸드란
시리쉬쿠마르 쿨카르니
프라빈 메그라지 부타다
아쉬쉬 아쇼크라오 데쉬무크
더글라스 바칸
미첼 워츠만
Original Assignee
메디시스 파마수티컬 코포레인션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디시스 파마수티컬 코포레인션 filed Critical 메디시스 파마수티컬 코포레인션
Publication of KR20160021074A publication Critical patent/KR20160021074A/ko
Application granted granted Critical
Publication of KR102298473B1 publication Critical patent/KR102298473B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157028585A 2013-03-15 2014-03-04 제어 방출 제약 투여 형태 Active KR102298473B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN304/KOL/2013 2013-03-15
IN304KO2013 2013-03-15
US13/890,173 US10842802B2 (en) 2013-03-15 2013-05-08 Controlled release pharmaceutical dosage forms
US13/890,173 2013-05-08
PCT/US2014/020251 WO2014149674A1 (en) 2013-03-15 2014-03-04 Controlled release pharmaceutical dosage forms

Publications (2)

Publication Number Publication Date
KR20160021074A KR20160021074A (ko) 2016-02-24
KR102298473B1 true KR102298473B1 (ko) 2021-09-03

Family

ID=54198667

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028585A Active KR102298473B1 (ko) 2013-03-15 2014-03-04 제어 방출 제약 투여 형태

Country Status (8)

Country Link
US (1) US10842802B2 (enExample)
EP (1) EP2968179B1 (enExample)
JP (1) JP6417532B2 (enExample)
KR (1) KR102298473B1 (enExample)
CN (2) CN105188683A (enExample)
AU (1) AU2014237934B2 (enExample)
CA (1) CA2906378C (enExample)
WO (1) WO2014149674A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528983B2 (en) * 2014-05-12 2016-12-27 Anna Merritt Holmes Physicochemical modification and application of alginate gels for the controlled release of reagents in classical solution assays and microfluidic assays
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
CA2968316A1 (en) 2014-11-19 2016-05-26 Nestle Skin Health Sa Modified release doxycycline composition
ITUB20150279A1 (it) * 2015-03-09 2016-09-09 S I I T S R L Servizio Int Imballaggi Termosaldanti Sistema flottante per la cura dei sintomi delle affezioni gastriche
TW202116314A (zh) * 2019-07-11 2021-05-01 美商普雷西斯精密藥品公司 T型鈣離子通道調節劑之調配物及其使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2006522162A (ja) 2003-04-07 2006-09-28 シャイア ラボラトリーズ，インコーポレイテッド テトラサイクリンの１日１回製剤
WO2007038867A1 (en) 2005-10-04 2007-04-12 Mistral Pharma Inc. Controlled-release oral dosage form
WO2010038234A1 (en) 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
US20100330131A1 (en) 2005-06-24 2010-12-30 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20120100214A1 (en) 2010-10-21 2012-04-26 Galderma S.A. Sustained-Release Tablet and Process for Preparing the Same

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
WO1996018370A1 (en) 1994-12-16 1996-06-20 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
JPH0995440A (ja) 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
CN1126537C (zh) 1996-05-23 2003-11-05 株式会社三养社 可局部给药,可生物降解和持续释放的用于治疗牙周炎的药物组合物及其制备方法
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
JP5093937B2 (ja) 1997-06-11 2012-12-12 味の素株式会社 上部胃腸管の安全性を高めるためのフィルムコーティング錠
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
PT1065936E (pt) 1998-03-23 2009-09-24 Gen Mills Inc Encapsulação de componentes em produtos comestíveis
ATE429813T1 (de) 1998-10-09 2009-05-15 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
CA2367373C (en) 1999-03-17 2011-09-20 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
WO2002024167A1 (fr) * 2000-09-19 2002-03-28 Daiichi Pharmaceutical Co., Ltd. Composition medicinale
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
IN192750B (enExample) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
JP2004525955A (ja) 2001-04-05 2004-08-26 コッラジェネックス ファーマシューチカルス インコーポレイテッド テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1465591A1 (en) 2001-12-20 2004-10-13 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
CA2478121A1 (en) 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
EP1494681A4 (en) 2002-04-16 2008-08-06 Collagenex Pharm Inc PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20050266077A1 (en) 2002-06-20 2005-12-01 Royal Biomedical, Inc. Resorbable matrices with coatings for delivery of bioactive compounds
PT1532985T (pt) 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Processo de produção de uma composição de libertação sustentada
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
JP2006522099A (ja) 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
WO2004096125A2 (en) 2003-04-14 2004-11-11 Shire Laboratories, Inc. Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
US20070110804A1 (en) 2003-06-20 2007-05-17 Royer Biomedical, Inc. Drug polymer complexes
US7485319B2 (en) 2003-07-25 2009-02-03 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
US20050049210A1 (en) 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
EP1677762A1 (en) 2003-10-27 2006-07-12 Dow Corning Corporation A controlled-release composition for topical application and a method of delivering an active agent to a substrate
WO2005046651A1 (en) 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Liquid filled capsules of doxycycline
ES2308274T3 (es) 2003-12-04 2008-12-01 Pfizer Products Inc. Procedimiento para fabricar multiparticulados farmaceuticos.
DE10358748A1 (de) 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform basierend auf vernetzten hydrophilen Polymeren
US7410480B2 (en) 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
DK2258349T3 (da) 2004-05-11 2014-10-13 Egalet Ltd Kvældbar doseringsform omfattende gellangummi
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
US20080161273A1 (en) 2004-10-20 2008-07-03 Galderma Research & Development Method of Using Adapalene in Acne Maintenance Therapy
WO2006045152A1 (en) 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Improved tabletting process
US20060147491A1 (en) 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20100215744A1 (en) 2008-08-06 2010-08-26 Medicis Pharmaceutical Corporation Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
EP1898886B1 (en) 2005-07-01 2019-09-04 Rubicon Research Pvt Ltd. Novel sustained release dosage form
AU2006264407B2 (en) 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
US20080248107A1 (en) 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2007087416A2 (en) 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
MX2008014059A (es) 2006-05-09 2008-11-14 Mallinckrodt Inc Formas de dosificacion solida de liberacion modificada en el orden de cero.
EP2032124A1 (en) 2006-06-27 2009-03-11 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014257A1 (en) 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
WO2008058288A2 (en) 2006-11-09 2008-05-15 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
SI2120963T1 (sl) 2006-12-21 2019-02-28 Paratek Pharmaceuticals, Inc. Substituirane spojine tetraciklina za zdravljenje vnetnih kožnih motenj
GB0703627D0 (en) 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
WO2008104996A2 (en) 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
AU2008231033B2 (en) 2007-03-23 2012-08-30 Molecular Research Center, Inc. Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
US20100202986A1 (en) 2007-07-11 2010-08-12 Victor Albert Raul Compositions For Delivering A Drug
CN101380474B (zh) 2007-09-06 2012-07-25 北京大学 用于口服制剂的pH敏感性固体药物组合物及制备方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2133071A1 (en) * 2008-06-09 2009-12-16 Université de la Méditerranée Process for making gastroretentive dosage forms
PL2299953T3 (pl) 2008-07-14 2017-10-31 Polypid Ltd Kompozycja nośnika leku o przedłużonym uwalnianiu
US20110268807A1 (en) 2008-08-04 2011-11-03 James Su Biodegradable Microspheres and Methods of Use Thereof
CA2737475A1 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CA2738114A1 (en) 2008-09-22 2010-04-08 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
DE102008048729A1 (de) 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
EP2331209A1 (en) 2008-10-02 2011-06-15 Bayer Consumer Care AG Compositions for treating or alleviating skin diseases or disorders related to an enhanced level of anti-microbial peptides and proteins
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
JP5723287B2 (ja) 2008-12-15 2015-05-27 バナー ライフ サイエンシズ エルエルシー 非水溶性活性薬剤の放出および吸収を増強するための方法
WO2010120892A2 (en) 2009-04-14 2010-10-21 The Regents Of The University Of California Improved oral drug devices and drug formulations
GB0907019D0 (en) 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
US20100291201A1 (en) 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
CN102459064A (zh) 2009-05-28 2012-05-16 西北大学 纳米金刚石粒子络合物
EP3144004A1 (en) 2009-10-06 2017-03-22 Scott Dorfner Antibiotic formulations providing reduced gastrointestinal side effects and clostridium difficile infection relapse, and related methods
EP3569223A1 (en) 2009-10-30 2019-11-20 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US20120082632A1 (en) 2010-04-21 2012-04-05 Phillips D Howard Topical drug delivery system with dual carriers
CA2802041A1 (en) 2010-06-11 2011-12-15 Precision Dermatology, Inc. High oil-content emollient aerosol foam compositions
US8652516B1 (en) 2013-03-15 2014-02-18 Cerovene, Inc. Doxycycline formulations, and methods of treating rosacea

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2006522162A (ja) 2003-04-07 2006-09-28 シャイア ラボラトリーズ，インコーポレイテッド テトラサイクリンの１日１回製剤
US20110319368A1 (en) 2003-04-07 2011-12-29 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
US20100330131A1 (en) 2005-06-24 2010-12-30 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
WO2007038867A1 (en) 2005-10-04 2007-04-12 Mistral Pharma Inc. Controlled-release oral dosage form
US20080318910A1 (en) 2005-10-04 2008-12-25 Mistral Pharma, Inc. Controlled-Release Oral Dosage Form
WO2010038234A1 (en) 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
US20120100214A1 (en) 2010-10-21 2012-04-26 Galderma S.A. Sustained-Release Tablet and Process for Preparing the Same
WO2012059338A1 (en) 2010-10-21 2012-05-10 Galderma S.A. Sustained-release tablet and process for preparing the same

Also Published As

Publication number Publication date
US10842802B2 (en) 2020-11-24
EP2968179A1 (en) 2016-01-20
JP6417532B2 (ja) 2018-11-07
CN105188683A (zh) 2015-12-23
CN112007007A (zh) 2020-12-01
CA2906378A1 (en) 2014-09-25
EP2968179B1 (en) 2019-11-06
WO2014149674A1 (en) 2014-09-25
AU2014237934B2 (en) 2019-01-24
JP2016516031A (ja) 2016-06-02
US20140274970A1 (en) 2014-09-18
AU2014237934A1 (en) 2015-09-24
CA2906378C (en) 2021-06-22
EP2968179A4 (en) 2016-08-31
KR20160021074A (ko) 2016-02-24

Similar Documents

Publication Publication Date Title
EP2011486B1 (en) Pharmaceutical compositions of rifaximin
AU2012320563B2 (en) Pharmaceutical compositions comprising 40 - O - ( 2 - hydroxy) ethyl - rapamycin
US20180161280A1 (en) Pharmaceutical compositions comprising everolimus
CN101489560A (zh) 具有s形释放曲线的奥卡西平控释制剂
CN101636152A (zh) 含有西洛他唑的控释制剂及其制备方法
WO2009084040A1 (en) Once a day formulation of angiotensin receptor blockers
KR102298473B1 (ko) 제어 방출 제약 투여 형태
US20100280035A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
US9675585B1 (en) Extended release pharmaceutical formulations
EP2386302A1 (en) A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
CA3230682A1 (en) Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis
HK40041911A (en) Controlled release pharmaceutical dosage forms
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
DK2674153T3 (en) Oral dosage form for the immediate release of bendroflumethiazide and controlled release of a second active agent
CN101784264A (zh) 用于延长释放的药物制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5